z-logo
open-access-imgOpen Access
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Author(s) -
Stefan D. Anker,
Javed Butler,
Gerasimos Filippatos,
João Pedro Ferreira,
Edimar Alcides Bocchi,
Michael Böhm,
HansPeter BrunnerLa Rocca,
DongJu Choi,
Vijay Chopra,
Eduardo ChuquiureValenzuela,
Nadia Giannetti,
Juan Esteban GómezMesa,
Stefan Janssens,
James L. Januzzi,
José Ramón González–Juanatey,
Béla Merkely,
Stephen J. Nicholls,
Sergio V. Perrone,
Ileana L. Piña,
Piotr Ponikowski,
Michele Senni,
David Sim,
Jindřich Špinar,
Iain Squire,
Stefano Taddei,
Hiroyuki Tsutsui,
Subodh Verma,
Dragoş Vinereanu,
Jian Zhang,
Peter E. Carson,
Carolyn S.P. Lam,
Nikolaus Marx,
Cordula Zeller,
Naveed Sattar,
Waheed Jamal,
Sven Schnaidt,
Janet Schnee,
Martina Brueckmann,
Stuart J. Pocock,
Faı̈ez Zannad,
Milton Packer
Publication year - 2021
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2107038
Subject(s) - empagliflozin , ejection fraction , heart failure , cardiology , medicine , fraction (chemistry) , heart failure with preserved ejection fraction , diabetes mellitus , chemistry , endocrinology , chromatography , type 2 diabetes
Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom